We extended these findings to HNSCC PDOs, where PRMT1 knockdown inhibited growth and enhanced CBP sensitivity—effects counteracted by IGF2BP2 overexpression (Figure 4E; Figure S7B, Supporting Information). The gene discussed is IGF2BP2; the disease is head and neck squamous cell carcinoma.